tiprankstipranks
Catalyst Pharma (CPRX)
NASDAQ:CPRX

Catalyst Pharma (CPRX) AI Stock Analysis

Compare
2,252 Followers

Top Page

CP

Catalyst Pharma

(NASDAQ:CPRX)

79Outperform
Catalyst Pharma demonstrates strong financial performance with significant growth and profitability, a solid balance sheet, and strong cash flow. Technical analysis presents mixed signals, while the valuation appears reasonable. The earnings call provided positive guidance, though there are concerns about FYCOMPA's revenue decline and increased expenses. The company is well-positioned for growth, particularly in the rare diseases sector.
Positive Factors
Litigation Outcome
Catalyst is well-positioned for favorable outcomes in the unresolved litigation with Hetero and Lupin, and the Firdapse patents are expected to be upheld.
Market Strategy
Strong penetration into the DMD market with a significant percentage of switches from prednisone and new enrollments from Emflaza.
Revenue Growth
Catalyst has delivered consistent double-digit year-over-year growth in Firdapse revenues.
Negative Factors
Generic Competition
Fycompa sales are likely to be negatively impacted this year by generic entry in May.
Patent Litigation
The trend of historical precedent suggests that when one first filer settles or is defeated, the others often follow suit within a reasonable timeframe.

Catalyst Pharma (CPRX) vs. S&P 500 (SPY)

Catalyst Pharma Business Overview & Revenue Model

Company DescriptionCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
How the Company Makes MoneyCatalyst Pharmaceuticals generates revenue primarily through the sale of its FDA-approved drug, Firdapse, which treats Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder. The company earns money by selling this product directly to patients through specialty pharmacies and by working with healthcare providers to ensure the availability of the medication to those in need. Additionally, Catalyst Pharma seeks to expand its revenue streams by developing and commercializing additional therapies for other rare diseases, which could include partnerships or collaborations with other pharmaceutical companies to enhance its product offerings and market reach. These strategic efforts allow Catalyst to maintain and potentially grow its sales and market presence in the orphan drug sector.

Catalyst Pharma Financial Statement Overview

Summary
Catalyst Pharma's financial performance is strong, with impressive revenue growth and profitability. The income statement shows 23.4% revenue growth and improved margins. The balance sheet is robust with low leverage and high liquidity. Cash flow is strong, despite past volatility.
Income Statement
92
Very Positive
Catalyst Pharma has demonstrated strong revenue growth, with a significant increase in total revenue from $398.2 million in 2023 to $491.7 million in 2024, marking a growth rate of approximately 23.4%. The company maintains a high gross profit margin of 100% due to its cost structure. The net profit margin improved from 17.9% in 2023 to 33.3% in 2024, indicating enhanced profitability. The EBIT and EBITDA margins are robust at 39.7%, showcasing efficient operational performance. Overall, the income statement reflects strong growth and profitability.
Balance Sheet
88
Very Positive
Catalyst Pharma exhibits a strong balance sheet with a low debt-to-equity ratio of 0.004, reflecting minimal leverage. The return on equity (ROE) is impressive at 22.5%, indicating effective use of equity capital to generate profits. The equity ratio is robust at 85.5%, demonstrating a solid equity base relative to total assets. The company's financial stability is reinforced by substantial cash and short-term investments, significantly exceeding its total debt, contributing to a healthy liquidity position.
Cash Flow
75
Positive
The company has shown strong cash flow generation with a significant increase in free cash flow from -$54.9 million in 2023 to $143.4 million in 2024. The operating cash flow to net income ratio is 0.88, indicating efficient cash conversion from net income. The free cash flow to net income ratio is 0.88, suggesting a strong ability to generate cash relative to earnings. However, the lack of positive free cash flow growth in previous years indicates potential volatility in cash flow generation.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
491.73M398.20M214.20M140.83M119.07M
Gross Profit
422.89M313.67M179.81M118.95M102.03M
EBIT
195.12M86.81M101.84M52.38M41.30M
EBITDA
195.12M119.69M101.84M52.38M41.30M
Net Income Common Stockholders
163.89M71.41M83.08M39.48M74.98M
Balance SheetCash, Cash Equivalents and Short-Term Investments
517.55M137.64M298.39M191.27M140.28M
Total Assets
851.41M470.11M375.63M237.79M192.35M
Total Debt
2.79M3.56M3.89M3.89M28.77K
Net Debt
-514.77M-134.08M-294.50M-167.55M-130.21M
Total Liabilities
123.78M82.23M75.21M30.96M22.76M
Stockholders Equity
727.63M387.88M300.42M206.83M169.60M
Cash FlowFree Cash Flow
143.37M-54.92M116.02M59.35M45.02M
Operating Cash Flow
143.60M143.60M116.05M60.37M45.03M
Investing Cash Flow
-293.50M-293.50M9.21M-11.02M-5.01M
Financing Cash Flow
-10.86M-10.86M1.69M-8.14M701.93K

Catalyst Pharma Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price23.07
Price Trends
50DMA
22.76
Positive
100DMA
22.31
Positive
200DMA
20.65
Positive
Market Momentum
MACD
0.71
Negative
RSI
55.79
Neutral
STOCH
55.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPRX, the sentiment is Neutral. The current price of 23.07 is below the 20-day moving average (MA) of 23.23, above the 50-day MA of 22.76, and above the 200-day MA of 20.65, indicating a neutral trend. The MACD of 0.71 indicates Negative momentum. The RSI at 55.79 is Neutral, neither overbought nor oversold. The STOCH value of 55.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CPRX.

Catalyst Pharma Risk Analysis

Catalyst Pharma disclosed 42 risk factors in its most recent earnings report. Catalyst Pharma reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Catalyst Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$2.93B17.6329.38%23.49%104.96%
78
Outperform
$67.45B16.0915.95%0.14%8.27%10.35%
78
Outperform
$12.87B30.688.05%17.35%151.40%
75
Outperform
$166.45B40.9867.55%2.95%18.64%-39.39%
64
Neutral
$124.29B-3.15%11.64%-114.72%
54
Neutral
$3.30B-214.50%29.01%23.93%
48
Neutral
$6.86B1.11-50.22%2.47%16.71%1.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CPRX
Catalyst Pharma
23.07
7.90
52.08%
AMGN
Amgen
294.39
32.43
12.38%
BMRN
BioMarin Pharmaceutical
60.26
-26.69
-30.70%
REGN
Regeneron
573.45
-368.04
-39.09%
VRTX
Vertex Pharmaceuticals
474.62
67.95
16.71%
RARE
Ultragenyx Pharmaceutical
32.43
-17.81
-35.45%

Catalyst Pharma Earnings Call Summary

Earnings Call Date: Feb 26, 2025 | % Change Since: 12.10% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth and successful product launches, particularly with AGAMREE and FIRDAPSE, supported by a strong financial position and favorable patent resolution. However, there are challenges with anticipated revenue decline for FYCOMPA due to patent expiry, increased SG&A expenses, and expected impacts from the Inflation Reduction Act.
Highlights
Record Revenue Growth
Total revenues grew by 23.5% year-over-year to $491.7 million in 2024, exceeding previous guidance.
Successful Launch of AGAMREE
AGAMREE's full-year net product revenue reached $46 million, surpassing revised guidance, with strong adoption across DMD Centers of Excellence.
FIRDAPSE Sustained Growth
FIRDAPSE achieved a record revenue of $306 million in 2024, with 14 consecutive quarters of 15% or more growth year-over-year.
Strong Financial Position
The company ended 2024 with $517.6 million in cash and no debt, enhancing capacity for strategic growth opportunities.
Favorable Patent Resolution
Secured a favorable resolution to the Teva patent litigation, prohibiting generic entry until February 2035.
Lowlights
FYCOMPA Revenue Decline
Anticipated revenue decline for FYCOMPA due to loss of exclusivity in 2025 and expected generic competition.
Increased SG&A Expenses
SG&A expenses increased to $177.7 million in 2024 from $133.7 million in 2023, driven by AGAMREE-related expenses.
Gross to Net Impact from IRA
Expected gross to net impact due to the Inflation Reduction Act, affecting Medicare Part D FIRDAPSE sales.
Company Guidance
In the recent conference call for Catalyst Pharmaceuticals, the management team provided comprehensive guidance on their anticipated financial performance and strategic initiatives for 2025. The company reported a robust revenue growth of 23.5% for 2024, reaching $491.7 million, driven by their key products including FIRDAPSE and the newly launched AGAMREE. For 2025, Catalyst forecasts total revenues between $545 million and $565 million, with FIRDAPSE expected to contribute $355 million to $360 million, AGAMREE between $100 million and $110 million, and FYCOMPA $90 million to $95 million. They highlighted a strong cash position of $517.6 million and no debt, enabling continued investment in growth opportunities. The company also emphasized ongoing efforts to protect FIRDAPSE's market position through successful patent litigation outcomes and strategies to enhance AGAMREE's adoption. Additionally, Catalyst is actively exploring accretive business development opportunities in the rare disease space to further bolster their portfolio and sustain growth.

Catalyst Pharma Corporate Events

Executive/Board ChangesShareholder Meetings
Catalyst Pharma Announces Board Member’s Departure
Neutral
Jan 24, 2025

On January 17, 2025, Charles B. O’Keeffe, an independent member of the Board of Directors of Catalyst Pharmaceuticals, announced he would not seek reelection at the 2025 annual stockholders’ meeting, concluding his long-standing service on the Board since 2004. His decision was not due to any disagreement with the company. The company plans to hire a recruitment firm to find a new director, marking a significant transition in its leadership structure.

Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Catalyst Pharma Highlights Growth in Rare Diseases Sector
Positive
Jan 13, 2025

Catalyst Pharmaceuticals has released a corporate presentation that outlines their strategic focus on rare diseases, particularly through their flagship product FIRDAPSE for Lambert Eaton myasthenic syndrome (LEMS) and the novel corticosteroid AGAMREE for Duchenne Muscular Dystrophy (DMD). The presentation highlights the company’s growth strategy, market opportunities, and patient-centric initiatives, showcasing their strong financial performance and future potential in expanding patient access and market penetration in these niche therapeutic areas.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.